



2025 Forced Labor, Child Labor and Human Rights Regulatory Disclosures

June 2026



Contents

1. Introduction	3
2. About Teva	3
3. Our Value Chain	4
4. Human Rights	4
5. Risk Areas in Teva's Operations and Supply Chain	5
6. Governance and Risk Management	6
7. Policies	6
8. Supplier Management and Audits	8
9. Raising Concerns	9
10. Internal and External Engagement	10
11. Assessing Performance	11
Annex A – United Kingdom	13
Annex B – Australia	15
Annex C – Canada	20
Annex D – Norway	21

1. Introduction

This statement is for the period 1 January to 31 December 2025 and is prepared to demonstrate compliance with:

- (i) section 54 of the UK Modern Slavery Act 2015;
- (ii) section 16 of the Commonwealth Modern Slavery Act 2018 (Cth) in Australia;
- (iii) Canada's Fighting Against Forced Labour and Child Labour in Supply Chains Act (S-211);
- (iv) the California Transparency in Supply Chains Act; and
- (v) the Norwegian Transparency Act 2022. It applies to the reporting entities listed in Appendix A-D and Teva Pharmaceuticals USA, Inc.

This statement details the actions we have taken to assess and respect fundamental human rights, including the right to freedom from forced labor and child labor, and the right to decent working conditions in our operations and supply chains.

Unless expressly stated otherwise, references to 'we', 'us', and 'our' refer to Teva Pharmaceutical Industries Ltd ("Teva"), including Teva Pharmaceuticals USA, Inc. and the reporting entities listed in Appendix A-D and their owned and controlled entities.

The content of this statement reflects inputs from the entities listed in Appendix A-D as well as Teva global functions, as relevant, and has been approved by the management of those companies.

2. About Teva


Teva is publicly traded on the New York Stock Exchange (NYSE:TEVA) and the Tel Aviv Stock Exchange (TASE:TEVA). We are transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For 125 years, our commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars, and pharmacy brands worldwide, we are dedicated to addressing patients' needs, both now and in the future. At Teva, **we are all in for better health.**

We operate worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the world. Today, our global network of capabilities consists of approximately 34,000 employees across 57 markets.

We have more than 1,900 products in our global portfolio and an evolving pipeline. Our portfolio of generic medicines covers 56% of treatments on the World Health Organization’s Essential Medicines List of important drugs that address key healthcare needs across the globe¹.

3. Our Value Chain

The following graphic outlines Teva’s value chain, detailing the key operational stages from supplier engagement and manufacturing to distribution and end-customer delivery.



4. Human Rights

Teva is committed to respecting human rights across our entire business and supply chain. This is not only the right thing to do, but also strengthens our ability to operate responsibly, builds trust with stakeholders, and contributes to a sustainable future for our business and society.

We support the spirit and provisions of the Universal Declaration of Human Rights and the subsequent guidance set forth in the United Nations Guiding Principles on Business and Human Rights as well as in the International Labour Organization’s (ILO) Declaration on Fundamental Principles and Rights at Work (Core Labour Standards). The latter is used as a guiding reference for our policies and approach to human rights. As a signatory of the United Nations Global Compact since 2010, we have formally and publicly confirmed our resolve to take all

¹ Source: IQVIA MIDAS MAT Q4 2025, Analysis of 38 countries.

measures that are reasonably possible to respect all individuals and uphold their human rights within our business and throughout our supply chain. Compliance with all applicable laws, regulations, and other requirements designed to protect human rights is fundamental to our corporate wellbeing and that by striving for excellence in this area, we also protect, enhance, and create value for our organization. This is consistent with our purpose, values, and Code of Conduct.

We commit to protecting employees' rights across our operations by:

- providing safe and healthy working conditions;
- maintaining zero tolerance for discrimination, harassment, or retaliation;
- respecting freedom of association and collective bargaining according to regulation; and
- prohibiting forced labor, modern slavery, and child labor.

We also commit to lawful work hours and rest, fair compensation in line with applicable legal requirements for wages and social benefits, and accessible channels to raise concerns in good faith without fear of retaliation. We expect our suppliers to uphold the same commitments throughout their own supply chains.

5. Risk Areas in Teva's Operations and Supply Chain

At Teva, we identify and assess our Sustainability-related impacts, risks, and opportunities (IROs), including those related to our supply chain, through our Double Materiality Assessment. This is voluntarily aligned with the European Sustainability Reporting Standards (ESRS) under the Corporate Sustainability Reporting Directive (CSRD). Within this context, we identified two potential material impacts related to human rights, specifically under the topic of employee health and safety – in our own operations and our supply chain. However, no material risks identified at present, following assessment, while recognizing sector-wide inherent risks.

Whilst not specific to Teva, external research² suggests that potential heightened human rights risks in the pharmaceutical sector may be related to occupational health and safety, inadequate wages and working hours, limited access to social protection, discrimination and gender inequality, restrictions on freedom of association, and risks of forced labor.

According to the same sectoral analysis, such labor-related risks are more likely to arise in specific parts of the value chain, particularly in manufacturing and research, and are often heightened in upstream supply chains and

² United Nations Environment Programme Finance Initiative (UNEP FI) desk-based sectoral analysis. It is informed by international human rights standards, existing research and public reporting, and cross-references to related sectors

lower-tier suppliers. Risks may be exacerbated where work is outsourced or intermediated, and where suppliers rely on temporary, migrant, or subcontracted workers, especially in jurisdictions with weaker labor protection. At present we have not identified these risks as likely, although we continue to monitor them through our Human Rights due diligence process in order to prevent and mitigate such issues should they arise.

6. Governance and Risk Management

Teva's human rights progress and results will be reported through Teva's sustainability governance structure, as needed. This structure includes the Sustainability Steering Committee, which is composed of members of Teva's Executive Management and is chaired by Teva's CEO, and also the Sustainability Global Forum, which is composed of senior managers.

Teva's Human Rights Working Group is composed of Corporate Sustainability, Global Compliance and Ethics, Global Human Resources, Global Environment, Health, Safety and Sustainability (EHS&S), and Global Procurement functions. It meets periodically to track the implementation of human rights processes and to assess the performance of the different components (risk assessment, preventive measures, remedial measures, and grievance mechanism).

7. Policies

Teva has established policies, positions, codes, and related commitments designed to mitigate against adverse human rights risks in our business and our supply chain. Employees and suppliers are expected to be aware of and comply with their obligations as set out in these documents:

Code of Conduct (“the Code”)

We believe that compliance with all applicable laws, regulations, and other requirements designed to protect human rights is fundamental to our corporate wellbeing and that, by striving for excellence in this area, we also protect, enhance, and create value for our organization. This is consistent with our purpose, values, and employee Code of Conduct (available in full at [Code of Conduct](#)).

Teva's Code of Conduct establishes the company's global standards for ethical behavior, legal compliance, and responsible business conduct. It applies to all employees worldwide and serves as a foundational document guiding decision-making and professional behavior across our operations.

Human rights are a core element of the Code. It affirms respect for fundamental human rights and human dignity, including equality, non-discrimination, and freedom from harassment or abuse. The Code explicitly rejects forced labor, child labor, human trafficking, and other forms of exploitation, and reflects internationally-recognized labor and human rights principles.

Position on Human Rights

The Position on Human Rights (available in full at: [teva-human-rights-position.pdf](#)) sets out Teva's primary commitments, roles, and responsibilities and summarizes our due diligence approach, including risk assessment, preventive and remedial measures, and effectiveness assessments.

Responsible Supply Chain Position and Supplier Code of Conduct ("SCoC")

Teva's Responsible Supply Chain Position (available in full at: [teva-responsible-supply-chain.pdf](#)) outlines our commitment to maintaining a responsible, ethical, and sustainable global supply chain aligned with our Healthy Future strategy. This is applicable to Teva-operated entities and all supply chain partners (i.e. Tier 1).

Our SCoC (available in full at: [Teva Supplier Code of Conduct | Teva Pharmaceuticals](#)) sets out our sustainability and human rights expectations for suppliers and outlines our approach to a responsible supply chain.

Teva's Suppliers are required, through applicable Terms & Conditions, to comply with Teva's Supplier Code of Conduct (SCoC). SCoC includes requirements, amongst others, that materials incorporated into Teva products comply with applicable laws relating to forced labor, child labor, human rights, and decent working conditions. In addition, our supplier Letter of Intent emphasizes Teva's expectation from our suppliers, including those covered in our SCoC.

Additional policies and positions

Teva has formal public commitments and statements that guide all our employees and suppliers on a range of human rights aspects. These include, but are not limited to, our:

- Global Prevention of Corruption Policy,
- Conflict Minerals Policy Statement,
- Position on Environmental Sustainability,
- Position on Pharmaceuticals in the Environment,
- Global Harassment Policy,
- Position on Inclusion and Diversity,
- Position on Talent Recruitment and Development,
- Position on Occupational Health and Safety,
- Position on Health Equity and Access to Medicines,
- Position on Pricing,
- Position on Clinical Trial Ethics & Transparency,

- Position on Patient Safety, and
- Position on Responsible and Ethical Use of Artificial Intelligence.

All of our public policies, positions and disclosures can be viewed [here](#).

We also have internal-facing policies and procedures, which set the corporate global expectations to be applied across the business. These include policies related to Environmental, Health, Safety and Sustainability, Recruitment, and Human Rights.

8. Supplier Management and Audits

Global Procurement embeds sustainability criteria into supplier selection, contracting, and performance management. This integrated approach has led to Teva receiving an EcoVadis score in the sustainable procurement theme of 87 (out of 100) in 2025, which places Teva in the top 1% for our sector.

Teva's policies dictate the use of risk-based assessment of suppliers. This considers, among other factors, the potential risk of non-compliance with our Supplier Code of Conduct (SCoC) and the suppliers' importance to Teva.

This risk-based approach incorporates our annual human rights risk screening, which evaluates risk exposure across both Teva's operations and its supplier base. We leverage EiQ, a centralized, real-time, AI-supported risk assessment platform, to screen Teva's and supplier's sites based on business relevance, human rights, and environmental risks. The platform covers risks across geographies, products and services, and sustainability topics, including labor, health and safety, environmental, business ethics, and management-system-related risks. Source data includes public indices, media screening results, and insights derived from thousands of audits performed annually.

In 2025, we screened approximately 5,500 supplier sites, including significant suppliers, as well as more than 100 Teva locations using EiQ. Sites are rated according to their risk exposure level (low, medium, high, or extreme). In parallel, suppliers are classified based on Teva's level of influence (low, medium, or high), which considers business relevance (volume of business) and the identification of significant suppliers. Our own operations are assessed within the same framework and are classified with an extreme influence rating.

Risk and influence ratings are plotted on a matrix to support prioritization and to determine where further due diligence actions may be warranted. Management implications and recommended actions are defined for each segment of the matrix, and the assessment outcomes can be integrated with additional due diligence tools.

For our significant suppliers and those suppliers presenting Human Rights high-risk exposure where we have a high level of influence, we complement our risk-based screening with additional assessment tools. These include:

- **Supplier self-assessments:** We use EcoVadis to assess the sustainability performance of suppliers and to benchmark them against industry peers. EcoVadis is a leading provider of business sustainability ratings, intelligence, and collaborative performance improvement tools for global supply chains. EcoVadis assessments include evaluation of labor and human rights, ethics, child/forced labor, sustainable procurement, and more. This assessment comprises desk-based assessments with systematic verification of evidence. All suppliers that achieve an insufficient EcoVadis performance rating receive a request for improvement through the implementation of corrective actions.

Third-party independent audits: Supplier on-site assessments, conducted on our behalf by third-party independent audit firms approved by the Pharmaceutical Supply Chain Initiative (PSCI), are scheduled in advance and verify compliance with Teva's Supplier Code of Conduct (SCoC) and identify potential risks and gaps in sustainability performance against the PSCI audit protocols. PSCI audits cover sustainability topics, such as Management Systems, Ethics (e.g. business integrity), Human Rights and Labor (e.g. freely chosen labor, wages, and working hours), Health and Safety (e.g. worker protection), and Environment.

As some of our sites supply local Teva markets, they are also assessed through the risk screening process. If a Teva site is identified as potentially high risk, additional internal evaluations are conducted to assess compliance with Teva policies and positions, and corrective action plans are developed when needed.

The Global Procurement process mentioned above is complemented by Teva's third-party representative (TPR) Due Diligence program. In this context, all submitted TPR business partners are evaluated for sanctions screening and checks related to bribery, corruption, and forced labor violations. We also frequently screen all vendors for sanctions and human rights violations.

9. Raising Concerns

Teva's efforts to addressing human rights-related risks also include the Office of Business Integrity ("OBI"). OBI manages Teva's Integrity **Hotline** complaints procedure – from initial intake and assessment through investigation and resolution – and serves as a trusted resource that supports our values and promotes a 'speak-up' culture. The Integrity Hotline is a channel for anyone to ask questions and report concerns about actual or suspected misconduct or non-compliance with Teva's Code of Conduct, values, policies, or applicable laws.

Employees, suppliers, and service providers are encouraged to report concerns or suspected illegal activities in the workplace to OBI, including concerns relating to human rights and ethical behavior, without fear of reprisal, intimidation, or harassment. Reports can be made anonymously where permitted by law and are handled through OBI's secure case management process, which is functionally independent from our business units.

More details are available in Teva's Integrity Hotline Complaints Procedure (available in full at: [tevas-integrity-hotline-complaints-procedure.pdf](#)).

Over the last three years, we have not had any substantiated reports categorized as human-rights-related.

Teva's Integrity Hotline telephone numbers are tested during the year to ensure they operate effectively, "based on information available through our reporting mechanisms.

We share anonymized examples of cases handled by OBI with employees, to bring these issues to life and support learning and ethical conduct.

10. Internal and External Engagement

Internal and external engagement are important parts of Teva's approach to raising awareness and strengthening understanding of human rights, employment practices, and related principles across our operations and supply chain. We engage employees, procurement leaders, and suppliers through targeted training, communications, and industry collaboration to reinforce our strong culture of compliance and ethics.

We expect our employees to be accountable for compliance. Within this context, we are committed to equipping our employees with the essential knowledge, skills, and resources needed to comply with the compliance and ethics standards outlined in the Teva Code of Conduct. New employees are required to complete foundational training covering various topics, including our Code of Conduct and other relevant policies. Supplementary training – including tailored in-person sessions – is provided for certain higher-risk functions.

All active employees participate in our long-running "Our Way" training program, an employee training series featuring numerous digital compliance courses designed to reinforce our compliance principles and commitment to integrity. Refresher training and active acknowledgement of our Code of Conduct, which encompasses guidance on confidential and anonymous reporting of misconduct or concerns through our OBI, is provided every other year for all active employees. Other compliance and ethics training campaigns target relevant populations of employees based on a risk-based job classification. In 2024, more than 99% of active employees were recertified on our Code of Conduct. The next refresher training for all employees is due in 2026. In 2025, around 99% of new employees were trained on our Code of Conduct and over 99% of our active employees completed their assigned compliance and ethics training. This included topics related to Trade Sanctions and Bribery and Corruption.

With respect to external engagement, we engage directly with suppliers through our annual Sustainability Webinar for significant suppliers. The webinar reinforces our SCoC and sustainability commitments, promotes the use of sustainability assessments to evaluate supplier's practices and impacts, and raises awareness of human rights and environmental regulations. In 2025, we welcomed more than 180 attendees representing 116 suppliers.

These engagement efforts also support progress toward our sustainable procurement targets, which aim to continue improving supplier engagement and development, as shown in the table below.

Target	Progress	Status
Evaluate 95% of significant suppliers ³ by spend on sustainability topics by 2030	66% of significant suppliers by spend with valid assessments ⁴	In Progress
Achieve 70% of significant suppliers by spend scoring >60 points in EcoVadis by 2030	49% of significant suppliers by spend have a score >60	In Progress

More details on our actions to meet these targets can be found in the 2025 Healthy Future Report.

We communicate policies and procedures externally, post key documents on our website, and include relevant language and references in purchase orders and contracts.

In 2025, we continued our long-term relationships with the Pharmaceutical Supply Chain Initiative (PSCI), the Pharmaceutical Environmental Group (PEG), and the Responsible Health Initiative (RHI), where we work with our peers to continue engaging our suppliers in sustainability and human rights.

11. Assessing Performance

At least once per year, Teva's Human Rights Working Group assesses the effectiveness of the Human Rights Risk Management process which is implemented to prevent or mitigate adverse human rights and environmental impacts. The group reviews the results of the measures implemented through effectiveness Key Performance Indicators (KPIs) and, when relevant, related thresholds.

If the results of the annual review indicate that the management approach is not meeting effectiveness expectations, appropriate action will be determined and implemented to improve them. These improvements can be related to roles and responsibilities, risk analysis and prioritization process, preventive measures, remedial action, complaints procedure, documentation, or other relevant aspects.

In 2025, this assessment included metrics such as number of sites screened in the risk analysis, number of Human Rights complaints, significant suppliers by spend on sustainability topics, and significant suppliers by spend scoring >60 points in EcoVadis.

³ Significant suppliers are identified based on a defined set of criteria, including highest spend, links to antimicrobial resistance (AMR) and those targeted for sustainability initiatives based on a sustainability maturity model. These suppliers collectively represent 38% of Category 1 Scope 3 GHG emissions

⁴ Teva's definition for valid assessment: <50pts score is valid for 12 months (annual re-assessment) and ≥50pts score is valid for 24 months (biannual re-assessment).

The Compliance and Ethics function also assesses effectiveness through a number of KPIs and controls that reflect Teva's management of human rights risks. Relevant examples include frequent screening of all existing vendors against human rights databases; KPIs that monitor employees' completion of their compliance and ethics training curriculum; KPIs that compare performance relative to peers in the Organizational Health Survey on compliance and ethics questions; and strong processes and controls to ensure that instances of ethical misconduct are raised, investigated, and, where substantiated, addressed through appropriate corrective actions.

Annex A – United Kingdom

UK Modern Slavery Act 2015

Each of the reporting entities named below (the “UK Reporting Entities”) are required to publish an annual Modern Slavery and Human Trafficking Statement under section 54 of the Modern Slavery Act 2015.

- Teva UK Limited (“Teva UK”)
- Norton Healthcare Limited (“Teva Runcorn”)
- Teva Pharma Holdings Limited

The UK Reporting Entities are included within our global compliance program which is discussed throughout this Statement. The Statement relates to all our activities in the UK.

1. About Teva UK Reporting Entities

Teva UK is a largely commercial organization, including sales, marketing, medical, and various support functions, such as finance and technology. There are two commercial offices (one of which includes a distribution center) in the UK. At Teva Runcorn, there is also have a large manufacturing facility and a significant Research and Development presence.

For the Reporting Period, our UK Reporting Entities had a combined headcount of 997.

All UK Reporting Entities’ employees are paid above the UK National Minimum Wage. We support family-friendly working patterns and employees can apply for flexible working if required. Employees are further supported by a comprehensive wellbeing program, which includes quarterly focused wellbeing events and the availability of mental health first aiders.

2. Teva UK Supply Chain

Teva UK’s most important suppliers are the related Teva entities that supply Teva UK with medicines that are distributed in the UK. Teva UK uses DHL as our main logistics service supplier for transportation of our products within the UK; they are required to comply with the Policies as set out in this Statement.


All suppliers to the UK Reporting Entities are made aware of, and are required to confirm their adherence to, Teva’s Supplier Code of Conduct and employees are also trained on the requirements.

3. UK Reporting Entities training

In 2025, 100% of Teva’s new hires in the UK completed the Code of Conduct training, instilling the importance of ethics and compliance from the start. In addition, 100% of UK employees were recertified in 2024 with the Code of Conduct refresher training.

The “Our Way” training program was rolled out between three separate training campaigns during the year and were completed by more than 99% of the active employees to whom they were assigned in the UK.

This statement was approved by the Board of Directors of Teva UK Limited and Teva Pharma Holdings Limited on 17 June 2026.



Kim Innes

Director of Teva UK Limited

This statement was approved by the Board of Directors of Norton Healthcare Limited on 17 June 2026



Stephen Charlesworth

Director of Norton Healthcare Limited

Annex B – Australia

1. Purpose and Scope

This Annex is an integral part of Teva’s 2025 Forced Labor, Child Labor and Human Rights Regulatory Disclosures for the reporting period 1 January 2025 to 31 December 2025 (“**Global Statement**”) and is prepared for the purposes of compliance with the Australian *Modern Slavery Act 2018 (Cth)* (“**Act**”).

This Annex together with the main body of the Global Statement (hereinafter this “**Statement**”), describes Teva’s approach to the management of human rights and modern slavery risks across its operations and supply chains in Australia (also referred to as “value chains” in the Global Statement). This Annex is designed as a jurisdictional overlay, adding Australia-specific disclosures to the Global Statement which applies equally across our activities in Australia.

2. Teva Australia (s16(1)(a))

Teva Pharmaceuticals Australia Pty Ltd (ACN 002 951 877) (incorporated as a private limited company under the *Corporations Act 2001 (Cth)*) is a reporting entity for the purposes of section 5 of the Act based on its consolidated revenue. It is required to submit a statement under the Act, which encompasses its direct operations and supply chains and those of its subsidiaries.


Teva Pharmaceuticals Australia Pty Ltd is the Australian parent entity and, together with its operating subsidiaries below, comprises “**Teva Australia**” for the purposes of this Statement under the Act:

- Teva Pharma Australia Pty Ltd (ACN 169 715 664);
- Medis Pharma Pty Ltd (ACN 109 225 747); and
- Teva Pharma (New Zealand) Limited (NZ Company No. 1190198).

As each member of Teva Australia operates consistently within the framework of Teva’s global programs, policies and procedures for Ethics, Compliance, Environmental, Social and Governance, this Statement has been prepared to cover the operations and supply chains of the Teva Australia Group as a whole.

3. Teva Australia’s structure, operations and supply chains (s16(1)(b))

Teva Australia conducts its business from one main site located at Epping Road, Macquarie Park, NSW (being the registered office of the Australian incorporated entities) and another site in Auckland, New Zealand. As at 31 December 2025, a total of 135 employees were employed by Teva Australia. They were mostly office-based, with eight field-based employees. Teva Australia’s group structure is shown below.



Teva Australia group structure chart for the 2025 reporting period

Teva Pharmaceuticals Australia Pty Ltd (the Australian Reporting Entity): This is the Australian parent company, wholly owned by Teva Pharmaceutical Investments Singapore Pte. Ltd. incorporated in Singapore. Teva Pharmaceuticals Australia is a research and development company specialising in the discovery and pre-clinical development of biopharmaceuticals. As of 31 December 2025, it had a total of 64 full time employees, and two external consultants. Staff work in offices and research laboratories. As shown above, Teva Pharmaceuticals Australia has three subsidiaries conducting business and two dormant subsidiaries. The operating entities are described in more detail below.

Teva Pharma Australia Pty Ltd: Teva Pharma Australia is the main commercial entity, incorporated in Australia and is a wholly-owned subsidiary of Teva Pharmaceuticals Australia Pty Ltd. It imports, sells, markets, and distributes pharmaceutical products (including specialty, generic, and over-the-counter medicines) on behalf of Teva into Australia and distributes primarily to pharmaceutical wholesalers across Australia. These wholesalers and distributors then on-sell to pharmacies, grocery chains, and hospitals. Teva Pharma Australia uses third parties for logistics (3PLs) and external warehousing. As of 31 December 2025, Teva Pharma had 62 employees (58 full time and four part time), and one external consultant.

Medis Pharma Pty Ltd: Medis Pharma is a business-to-business commercial entity, incorporated in Australia and is wholly owned by Teva Pharmaceuticals Australia Pty Ltd. It specializes in the commercialization and supply of generic pharmaceutical finished products to business customers. Medis Pharma has three employees based in Australia, with the rest based in other countries, principally Iceland. The finished goods that it supplies to customers are sourced directly from either Teva’s global manufacturing sites or third party manufacturers located overseas. As at 31 December 2025, it had 3 full time employees.

Teva Pharma (New Zealand) Ltd: Teva Pharma (New Zealand) is a private limited company incorporated under New Zealand law and located in Auckland, New Zealand. It imports and markets specialty, generic, and over-the-counter finished pharmaceutical products in New Zealand. It sells to wholesale customers who are then responsible for distribution to pharmacies, hospitals, and district health boards, as well as into major grocery and other channels. As at 31 December 2025, it had 6 full time employees.

Teva Australia's supply chain involves direct and indirect procurement to perform its day-to-day business activities. More than 300 suppliers provided goods and services directly to Teva Australia in the prior reporting period; the majority (approximately 75%) were Australian or New Zealand-based suppliers, with the remainder located in various countries overseas (including Teva's internal network) with varying levels of modern slavery risk. This has not materially changed since the last reporting period.

The goods and services procured by Teva Australia are varied across its operations. Based on the total supplier base, the categories of supplier spend can be consolidated and classified as outlined below:

Supply of Manufactured Finished Goods (internally and externally sourced)	77%
Research, Development & Laboratory Services	6%
Laboratory Supplies & Equipment	5%
Facilities (e.g. utilities, rent, IT, facilities management)	3%
Professional Services & Consulting (e.g. financial, corporate, legal, regulatory)	3%
Warehousing, Freight & Logistics	2%
Marketing, Events, Meetings & Promotional	2%
HR Benefits and Services	1%
Memberships, Regulatory Fees and Other	1%

Suppliers of goods and services to Teva Australia are subject to the Global Procurement supplier management screening, compliance, and performance management tools as summarized in the Global Statement.

4. Modern slavery risks in Teva Australia's operations and supply chains (s16(1)(c))

Teva Australia's workforce is primarily office-based and its activities in Australia and New Zealand involve pharmaceutical research, development, sales, marketing, and distribution conducted under applicable laws (including medical, quality and safety). Teva Australia is of the view that the risk of modern slavery within its direct workforce in Australia is therefore low, consistent with Australia's low risk ranking in the Global Slavery Index published by Walk Free®.

As noted in section 5 of the Global Statement, Teva Australia recognises that heightened modern slavery risk is more likely to arise in upstream, multi-tier supply chains and in outsourced or intermediated labour, such as

certain third-party services (e.g., cleaning, security, facilities, labour hire, logistics, and warehousing) and internationally-sourced goods from regions where risks may be higher.

5. Additional actions taken by Teva Australia to assess modern slavery (s16(1)(d))

In the reporting period, additional actions were taken by Teva as outlined in the Global Statement (which includes on behalf of Teva Australia with respect to its supply chains and activities, where relevant). This included extensive screening of supplier sites as described in section 8 of the Global Statement, of which 11 sites/vendors were located in Australia.

As highlighted in section 10 of the Global Statement, as part of the 2025 Our Way Campaign, Teva Australia rolled out in-depth training on topics included within Teva's Code of Conduct and achieved a 99.5% completion rate across the Teva Australia entities.

Teva Australia started working on additional actions for the next reporting period, including the provision of modern slavery specific awareness training for its employees, in order to supplement the existing training on the Code of Conduct.

6) Assessing effectiveness in Australia (s16(1)(e))

As reported in the Global Statement, Teva assesses the effectiveness of its actions by monitoring its EcoVadis score, which has been maintained at 87 (out of 100) in 2025, placing us in the top 1% of our sector. Teva Australia is included within the scope of the assessment conducted by Teva's Human Rights Working Group as described in section 11 of the Global Statement.

In addition, effectiveness is assessed locally by Teva Australia by monitoring and comparing year-on-year data metrics from the implemented processes outlined in this Statement, such as:

- number of modern slavery / human rights complaints through the OBI;
- numbers of suppliers who are excluded from procurement processes based on modern slavery risks (or refusal to accept Teva's Supplier Code of Conduct); and
- any audit findings and corrective actions relating to modern slavery / human rights risks (if any).

7) Consultation (s16(1)(f))

This Statement was compiled in consultation with personnel from relevant global Teva functions and from each member of Teva Australia. Cross-functional and cross-jurisdictional working groups were established, with representatives from Global Sustainability Reporting & Engagement, Compliance, Regulatory, and Legal teams, who met to consider, review, and finalize the content. The content of this Statement was considered by the local Australian working group specifically against the reporting requirements of the Act.

8) Other information (s16(1)(g))

Teva Australia recognises that this is an ongoing and evolving process to identify and address modern slavery risks arising in our operations and supply chains. The Board of Teva Pharmaceuticals Australia Pty Ltd, the parent company of Teva Australia, will review the progress of the ongoing and proposed activities described in this Statement.

9) Approval

As outlined in this Statement, each member of Teva Australia is in the same industry and part of the Teva global group of companies with a common ultimate parent company, which prescribes common global policies and processes across their respective operations and supply chains. In accordance with section 13 of the Act, this Statement has been approved by the principal governing body (Board of Directors) of Teva Pharmaceuticals Australia Pty Ltd, as the parent entity of Teva Australia, on 17th June 2026.

Digitally signed by Anthony Doyle

Date: 2026.06.26 07:28:13 +10'00'

Anthony Doyle

Chairman, Teva Pharmaceuticals Australia Pty Ltd

Annex C – Canada

Each of the reporting entities named below (the “Canadian Reporting Entities”) are required to submit a statement under the Canadian Fighting Against Force Labour and Child Labour in Supply Chains Act (the “Canadian Act”).

Teva Canada Reporting Entities, structure and activities

This statement is being filed with respect to the activities of Teva Canada Limited, and Teva Canada Innovation G.P.-S.E.N.C. (collectively “Teva Canada”). Teva Canada Limited is a subsidiary of Teva Pharmaceutical Industries Limited (“Teva”), a corporation incorporated pursuant to the laws of Israel.

Teva Canada Limited and Teva Canada Innovation G.P.-S.E.N.C. are corporations incorporated pursuant to the laws of Canada. This report is being filed as a joint report for Teva Canada, in accordance with section 11(2)(b) of the Canadian.

Originally named Novopharm Limited, Teva Canada specializes in the development, production, and marketing of high-quality generic and biosimilar prescription pharmaceuticals and through our branded division, focuses on a diverse line of innovative products in a variety of therapeutic areas, such as central nervous system, pain care, respiratory, and oncology.

Teva Canada offers three “Centres for Excellence” for pharmaceutical manufacturing. These facilities provide high-quality, affordable pharmaceutical products, and they are integral players in Teva’s worldwide manufacturing network. With more than 850 people employed by Teva Canada, the majority of the medicines Teva Canada sells in Canada are made in Canada.

Attestation

This report has been approved by the Board of Directors of Teva Canada Limited on its own behalf and on behalf of Teva Canada Innovation in accordance with section 11(4)(b)(i) of the Canadian Act.

Annex D – Norway

Norwegian Transparency Act

Teva Norway AS (“Teva”) is required under the Norwegian Transparency Act to submit a statement on Human Rights and Decent Working Conditions. This statement relates to all Teva’s activities in Norway and sets out the steps we have taken to support and safeguard human rights and decent working conditions within our business and supply chain.

1. Our operations in Norway

Teva Norway AS, headquartered in Kinoveien 3a, 1337 Sandvika, Norway, operates as a sales and marketing company and had revenues of approximately €49.2m in 2025. It employs 15 people and collaborates with suppliers and business partners (the majority which are pharmaceutical related), and wholesalers in Norway.

Being a wholly-owned subsidiary of Teva Pharmaceutical Industries Limited, Teva Norway AS is subject to our global policies, processes and memberships.

2. Our trainings in Norway

Teva conducts refresher training for all employees on the Code of Conduct every other year. 100% of Norwegian employees were recertified in 2024.

The “Our Way” training program was rolled out through three separate training campaigns during the year and was completed by 100% of the active employees to whom they were assigned in Norway.

3. Raised concerns in Norway

No reports made to Teva’s Office of Business Integrity in 2025 were related to Teva in Norway.

4. Right to information

Upon written request, any person has the right to information from Teva regarding how Teva addresses actual and potential adverse impacts with respect to Teva’s Norwegian business activities and its supply chain. Please send request to: Email: post@tevapharm.no

This statement was approved by the Board of Directors of Teva Norway AS on 18^h June 2026

Per Morten Hamar

Per Morten Hamar

General Manager, Teva Norway AS

Kim Peetz

Digitally signed by Kim Peetz
Date: 2026.06.25 09:45:44 +02'00'

Kim Peetz

Finance Lead, Teva Norway AS